The programme's non-dilutive grant range and global eligibility align well with the venture's pre-seed stage and EU target geography. The focus on health innovation and pre-competitive MedTech matches the AI/biotech drug resistance prediction technology, though the venture's proof-of-concept validation and lack of incorporation may require careful positioning.